Acthera Therapeutics AG

Today, patients are exposed to unwanted side effects of drugs. With the use of our technology, we can control and target the delivery of drugs with an adaptable and versatile system built around the Hard-Shelled Liposomes (HSLs). We aim to address an unmet need in acute cardiovascular events, such as acute ischemic stroke and acute myocardial infractions, by increasing the efficacy and safety of thrombolytic drugs.

Join us in supporting this ambitious project. Together, we will transform medical therapy and improve the outcomes of patients suffering from acute ischemic stroke and acute myocardial infraction in the near future.